Nishanth Thalambedu

Assistant Professor

UAMS

Last publication 2026 Last refreshed 2026-05-16

faculty

Internal Medicine, College of Medicine

8 h-index 65 pubs 237 cited

Research Areas

Links

Research Group UAMS TRI Profile

OverviewAI-generated summary

Nishanth Thalambedu, Assistant Professor in Internal Medicine at the University of Arkansas for Medical Sciences, researches clinical outcomes and treatment trends in hematologic malignancies and cardiovascular diseases. His work includes an investigation into the clinical outcomes of patients with relapsed refractory multiple myeloma undergoing BCMA-directed CAR-T therapy, as well as a meta-analysis comparing transcatheter aortic valve replacement (TAVI) with surgical aortic valve replacement (SAVR) in patients with degenerated bioprosthetic aortic valves. He has also examined corneal toxicity associated with belantamab mafodotin and the feasibility of outpatient stem cell transplantation for multiple myeloma. His publications address topics such as the role of vertebral augmentation in multiple myeloma management and trends in TAVI and SAVR for both cancer and non-cancer patient populations. Thalambedu's scholarship metrics include an h-index of 7, with 65 total publications and 224 citations.

Metrics

h-index: 8
Publications: 65
Citations: 237

Selected Publications

Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL (2026)

DOI OpenAlex
Impact of the CAR-T era on survival in diffuse large B-cell lymphoma: A u.S. population-based cohort study (2025)

DOI OpenAlex
Editorial: Progressive role of artificial intelligence in treatment decision-making in the field of medical oncology (2025)

DOI OpenAlex
Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature (2025)

4 citations DOI OpenAlex
Integrating artificial intelligence with circulating tumor DNA for non-small cell lung cancer: opportunities, challenges, and future directions (2025)

6 citations DOI OpenAlex
Role of proliferation-related genes as predictive factors for adjuvant therapy in colon cancer. (2025)

DOI OpenAlex
Abstract 1124: Mining the Kras-p53 mutational interface for synthetic lethality (SL) in pancreatic adenocarcinoma (PA) (2025)

DOI OpenAlex
Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances (2025)

3 citations DOI OpenAlex
Eculizumab for Hyperhemolysis in Sickle Cell Disease: Key Insights From a Challenging Case (2024)

DOI OpenAlex
Demographics and Survival Outcomes of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Retrospective Analysis of SEER Database (2024)

DOI OpenAlex
HL-697 Demographics and Survival Outcomes of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Retrospective Analysis of SEER Database (2024)

DOI OpenAlex
Abstract B009: Exploring the putative Kras-p53 mutational interface for vulnerability (2024)

DOI OpenAlex
Demographics and survival outcomes of stage IV male breast cancer: A retrospective analysis of SEER database. (2024)

DOI OpenAlex
CLO24-090: Demographics and Outcomes of Autologous Stem Cell Transplant Among IgD Multiple Myeloma Patients (2024)

DOI OpenAlex
The Role of Vertebral Augmentation Procedures in the Management of Multiple Myeloma (2024)

6 citations DOI OpenAlex